HUMAW
Humacyte, Inc. NASDAQ$0.08
Mkt Cap $98.6M
52w Low $0.08
1.9% of range
52w High $0.23
50d MA $0.10
200d MA $0.20
P/E (TTM)
-0.3x
EV/EBITDA
-1.7x
P/B
4.2x
Debt/Equity
20.9x
ROE
-1313.4%
P/FCF
-1.4x
RSI (14)
—
ATR (14)
—
Beta
2.10
50d MA
$0.10
200d MA
$0.20
Avg Volume
19.1K
About
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without i…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.13 | -0.13 | +1.2% | 0.09 | +5.7% | +0.5% | +3.0% | +0.3% | +4.7% | +5.7% | — |
| Nov 12, 2025 | AMC | -0.15 | -0.11 | +26.7% | 0.18 | +0.0% | +7.6% | +7.6% | -8.5% | -9.3% | -12.2% | — |
| Aug 11, 2025 | AMC | -0.16 | -0.24 | -49.8% | 0.24 | +3.3% | +7.4% | -3.2% | +23.9% | +14.7% | +21.9% | — |
| May 13, 2025 | AMC | -0.19 | 0.30 | +255.7% | 0.43 | +14.0% | +27.4% | +13.9% | +27.9% | +4.7% | +20.9% | — |
| Sep 30, 2023 | AMC | — | -0.00 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.00 | — | 0.73 | +1.4% | +1.4% | +2.7% | +8.2% | +9.5% | +4.1% | — |
| Mar 31, 2023 | AMC | — | -0.00 | — | 0.60 | +2.7% | +1.7% | +23.8% | +6.7% | +9.1% | +26.6% | — |
| Dec 31, 2022 | AMC | — | 0.00 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.65 | $3.94 | +7.9% | +4.7% | +8.8% | +4.1% | +3.6% | -1.9% |
Data updated apr 28, 2026 11:20am
· Source: massive.com